Nicole Lamanna, MD, Columbia University Medical Center, New York, NY, gives an overview of the key talking points from a symposium at SOHO 2021 on the efficacy and rationale for the use of Bruton’s tyrosine kinase (BTK) inhibitors in different subtypes of chronic lymphocytic leukemia (CLL). Dr Lamanna comments on the safety profiles of different BTK inhibitors, the comparison of ibrutinib with second-generation BTK inhibitors, and the development of novel, non-covalent BTK inhibitors such as pirtobrutinib. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.